Based on these encouraging reports we hypothesize that targeting GPC-1 alone or in combination with PI3K inhibitors may offer an attractive alternative strategy to improve drug sensitivity and overcome drug resistance in refractory cancers such as EAC. This evidence concerns the gene GPC1 and cancer.